AMGN Quote, Financials, Valuation and Earnings

Merck & has a net margin of 33.28% compared to Amgen's net margin of 18.95%. Amgen's return on equity of 65.35% beat Merck &'s return on equity of 29.26%.

Amgen has a consensus price target of $322.43, signalling upside risk potential of 21.91%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.44%. Given that Merck & has higher upside potential than Amgen, analysts believe Merck & is more attractive than Amgen.

Amgen has a beta of 0.547, which suggesting that the stock is 45.307% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.4%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Amgen pays 67.83% of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

Amgen quarterly revenues are $8.5B, which are smaller than Merck & quarterly revenues of $16.7B. Amgen's net income of $2.8B is lower than Merck &'s net income of $3.2B. Notably, Amgen's price-to-earnings ratio is 33.87x while Merck &'s PE ratio is 20.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.38x versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 33.28% compared to Amgen's net margin of 25.23%. Amgen's return on equity of 65.35% beat Pfizer's return on equity of 4.63%.

Amgen has a consensus price target of $322.43, signalling upside risk potential of 21.91%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Amgen has higher upside potential than Pfizer, analysts believe Amgen is more attractive than Pfizer.

Amgen has a beta of 0.547, which suggesting that the stock is 45.307% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.4%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Amgen pays 67.83% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Amgen quarterly revenues are $8.5B, which are smaller than Pfizer quarterly revenues of $17.7B. Amgen's net income of $2.8B is lower than Pfizer's net income of $4.5B. Notably, Amgen's price-to-earnings ratio is 33.87x while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.38x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 33.28% compared to Amgen's net margin of 36.03%. Amgen's return on equity of 65.35% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Amgen has a consensus price target of $322.43, signalling upside risk potential of 21.91%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.39%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

Amgen has a beta of 0.547, which suggesting that the stock is 45.307% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.4%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 67.83% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen quarterly revenues are $8.5B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Amgen's net income of $2.8B is higher than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Amgen's price-to-earnings ratio is 33.87x while Regeneron Pharmaceuticals's PE ratio is 17.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.38x versus 5.94x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 33.28% compared to Amgen's net margin of --. Amgen's return on equity of 65.35% beat Viking Therapeutics's return on equity of --.

Amgen has a consensus price target of $322.43, signalling upside risk potential of 21.91%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 159.74%. Given that Viking Therapeutics has higher upside potential than Amgen, analysts believe Viking Therapeutics is more attractive than Amgen.

Amgen has a beta of 0.547, which suggesting that the stock is 45.307% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.4%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 67.83% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen quarterly revenues are $8.5B, which are larger than Viking Therapeutics quarterly revenues of --. Amgen's net income of $2.8B is higher than Viking Therapeutics's net income of -$24.9M. Notably, Amgen's price-to-earnings ratio is 33.87x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.38x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.